sibutramine has been researched along with Froehlich's Syndrome in 1 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Excerpt | Relevance | Reference |
---|---|---|
"The clinically and statistically significant weight reduction caused by sibutramine in this short-term study indicates that treatment of hypothalamic and syndromal obesity with this drug may be beneficial." | 9.12 | Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. ( Danielsson, P; Janson, A; Marcus, C; Norgren, S, 2007) |
"The clinically and statistically significant weight reduction caused by sibutramine in this short-term study indicates that treatment of hypothalamic and syndromal obesity with this drug may be beneficial." | 5.12 | Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. ( Danielsson, P; Janson, A; Marcus, C; Norgren, S, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Danielsson, P | 1 |
Janson, A | 1 |
Norgren, S | 1 |
Marcus, C | 1 |
1 trial available for sibutramine and Froehlich's Syndrome
Article | Year |
---|---|
Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes.
Topics: Absorptiometry, Photon; Adolescent; Adult; Antidepressive Agents; Body Weight; Child; Child, Prescho | 2007 |